PCSA — Processa Pharmaceuticals Cashflow Statement
0.000.00%
Last trade - 00:00- $15.29m
- $8.99m
Annual cashflow statement for Processa Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -14.4 | -11.4 | -27.4 | -11.1 | -11.9 |
| Depreciation | |||||
| Amortisation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | 11.6 | 3.63 | 16.5 | 2.45 | 0.717 |
| Unusual Items | |||||
| Purchased R&D | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -0.14 | -1.18 | 0.544 | 0.605 | -0.112 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Cash from Operating Activities | -3.14 | -8.72 | -9.61 | -8.06 | -11.2 |
| Capital Expenditures | — | — | — | -0.003 | -0.003 |
| Purchase of Fixed Assets | |||||
| Cash from Investing Activities | — | — | — | -0.003 | -0.003 |
| Financing Cash Flow Items | -0.095 | -0.251 | -0.089 | -0.053 | -0.024 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 17.9 | 9.8 | -0.389 | 6.27 | 7.73 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 14.7 | 1.08 | -9.99 | -1.8 | -3.51 |